Skip to main content
. Author manuscript; available in PMC: 2017 Jul 10.
Published in final edited form as: J Clin Oncol. 2016 Mar 21;34(20):2359–2365. doi: 10.1200/JCO.2015.63.1960

Fig 2.

Fig 2

(A, B) Median time to first progression and (C, D) 2-year overall survival by risk group among estrogen receptor positive (n=85) and ER positive/HER2 negative (n=69) patients presenting with de novo stage IV disease. Abbreviations: ER, estrogen receptor; IHC, immunohistochemistry; RS, recurrence score.